<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34680460</PMID><DateRevised><Year>2021</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Immune Responses against SARS-CoV-2-Questions and Experiences.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1342</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines9101342</ELocationID><Abstract><AbstractText>Understanding immune reactivity against SARS-CoV-2 is essential for coping with the COVID-19 pandemic. Herein, we discuss experiences and open questions about the complex immune responses to SARS-CoV-2. Some people react excellently without experiencing any clinical symptoms, they do not get sick, and they do not pass the virus on to anyone else ("sterilizing" immunity). Others produce antibodies and do not get COVID-19 but transmit the virus to others ("protective" immunity). Some people get sick but recover. A varying percentage develops respiratory failure, systemic symptoms, clotting disorders, cytokine storms, or multi-organ failure; they subsequently decease. Some develop long COVID, a new pathologic entity similar to fatigue syndrome or autoimmunity. In reality, COVID-19 is considered more of a systemic immune-vascular disease than a pulmonic disease, involving many tissues and the central nervous system. To fully comprehend the complex clinical manifestations, a profound understanding of the immune responses to SARS-CoV-2 is a good way to improve clinical management of COVID-19. Although neutralizing antibodies are an established approach to recognize an immune status, cellular immunity plays at least an equivalent or an even more important role. However, reliable methods to estimate the SARS-CoV-2-specific T cell capacity are not available for clinical routines. This deficit is important because an unknown percentage of people may exist with good memory T cell responsibility but a low number of or completely lacking peripheral antibodies against SARS-CoV-2. Apart from natural immune responses, vaccination against SARS-CoV-2 turned out to be very effective and much safer than naturally acquired immunity. Nevertheless, besides unwanted side effects of the currently available vector and mRNA preparations, concerns remain whether these vaccines will be strong enough to defeat the pandemic. Altogether, herein we discuss important questions, and try to give answers based on the current knowledge and preliminary data from our laboratories.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mangge</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kneihsl</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnedl</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-5212-5230</Identifier><AffiliationInfo><Affiliation>Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Practice for General Internal Medicine, Dr. Theodor K&#xf6;rnerstrasse 19b, A-8600 Bruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sendlhofer</LastName><ForeName>Gerald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Executive Department for Quality and Risk Management, University Hospital Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Unit for Safety in Health, Department of Surgery, Medical University of Graz, 8036 Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curcio</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-9070-4807</Identifier><AffiliationInfo><Affiliation>Department of Medical Area, University of Udine, 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domenis</LastName><ForeName>Rossana</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-2164-8899</Identifier><AffiliationInfo><Affiliation>Department of Medical Area, University of Udine, 33100 Udine, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">T and B cell responses</Keyword><Keyword MajorTopicYN="N">development of the COVID-19 pandemic</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34680460</ArticleId><ArticleId IdType="pmc">PMC8533170</ArticleId><ArticleId IdType="doi">10.3390/biomedicines9101342</ArticleId><ArticleId IdType="pii">biomedicines9101342</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kim D.S., Rowland-Jones S., Gea-Mallorqui E. Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020) Front. Immunol. 2020;11:571481. doi: 10.3389/fimmu.2020.571481.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.571481</ArticleId><ArticleId IdType="pmc">PMC7756008</ArticleId><ArticleId IdType="pubmed">33362759</ArticleId></ArticleIdList></Reference><Reference><Citation>Poland G.A., Ovsyannikova I.G., Kennedy R.B. SARS-CoV-2 immunity: Review and applications to phase 3 vaccine candidates. Lancet. 2020;396:1595&#x2013;1606. doi: 10.1016/S0140-6736(20)32137-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32137-1</ArticleId><ArticleId IdType="pmc">PMC7553736</ArticleId><ArticleId IdType="pubmed">33065034</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U., Muik A., Derhovanessian E., Vogler I., Kranz L.M., Vormehr M., Baum A., Pascal K., Quandt J., Maurus D., et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594&#x2013;599. doi: 10.1038/s41586-020-2814-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2814-7</ArticleId><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Awadasseid A., Wu Y., Tanaka Y., Zhang W. Current advances in the development of SARS-CoV-2 vaccines. Int. J. Biol. Sci. 2021;17:8&#x2013;19. doi: 10.7150/ijbs.52569.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.52569</ArticleId><ArticleId IdType="pmc">PMC7757035</ArticleId><ArticleId IdType="pubmed">33390829</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchini M., Liumbruno G.M., Pezzo M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. Eur. J. Haematol. 2021;107:173&#x2013;180. doi: 10.1111/ejh.13665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13665</ArticleId><ArticleId IdType="pmc">PMC8239516</ArticleId><ArticleId IdType="pubmed">33987882</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu Mouch S., Roguin A., Hellou E., Ishai A., Shoshan U., Mahamid L., Zoabi M., Aisman M., Goldschmid N., Berar Yanay N. Myocarditis following COVID-19 mRNA vaccination. Vaccine. 2021;39:3790&#x2013;3793. doi: 10.1016/j.vaccine.2021.05.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.087</ArticleId><ArticleId IdType="pmc">PMC8162819</ArticleId><ArticleId IdType="pubmed">34092429</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargano J.W., Wallace M., Hadler S.C., Langley G., Su J.R., Oster M.E., Broder K.R., Gee J., Weintraub E., Shimabukuro T., et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices&#x2014;United States, June 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:977&#x2013;982. doi: 10.15585/mmwr.mm7027e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7027e2</ArticleId><ArticleId IdType="pmc">PMC8312754</ArticleId><ArticleId IdType="pubmed">34237049</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., Yi S., Zhang J., Lv Z., Zhu C., Zhang Y. Viral Load Dynamics in Sputum and Nasopharyngeal Swab in Patients with COVID-19. J. Dent. Res. 2020;99:1239&#x2013;1244. doi: 10.1177/0022034520946251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0022034520946251</ArticleId><ArticleId IdType="pmc">PMC7399563</ArticleId><ArticleId IdType="pubmed">32744907</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheny M., Maleque N., Channell N., Eisch A.R., Auld S.C., Banerji A., Druey K.M. Severe Exacerbations of Systemic Capillary Leak Syndrome After COVID-19 Vaccination: A Case Series. Ann. Intern. Med. 2021 doi: 10.7326/L21-0250.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/L21-0250</ArticleId><ArticleId IdType="pmc">PMC8252024</ArticleId><ArticleId IdType="pubmed">34125573</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E.Y., Team Y.I., Mao T., Klein J., Dai Y., Huck J.D., Jaycox J.R., Liu F., Zhou T., Israelow B., et al. Diverse Functional Autoantibodies in Patients with COVID-19. Nature. 2021;595:283&#x2013;288. doi: 10.1038/s41586-021-03631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., Dorgham K., Philippot Q., Rosain J., Beziat V., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370 doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Estes S.K., Ali R.A., Gandhi A.A., Yalavarthi S., Shi H., Sule G., Gockman K., Madison J.A., Zuo M., et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 2020;12 doi: 10.1126/scitranslmed.abd3876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., Wong P., Klein J., Castro T.B.R., Silva J., Sundaram M., Ellingson M.K., Mao T., Oh J.E., Israelow B., et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463&#x2013;469. doi: 10.1038/s41586-020-2588-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat. Med. 2021;27:28&#x2013;33. doi: 10.1038/s41591-020-01202-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01202-8</ArticleId><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Farshbafnadi M., Zonouzi S.K., Sabahi M., Dolatshahi M., Aarabi M.H. Aging &amp; COVID-19 susceptibility, disease severity, and clinical outcomes: The role of entangled risk factors. Exp. Gerontol. 2021;154:111507. doi: 10.1016/j.exger.2021.111507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2021.111507</ArticleId><ArticleId IdType="pmc">PMC8329427</ArticleId><ArticleId IdType="pubmed">34352287</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin M.T., Fatema K., Arefin S., Hussain F., Bhowmik D.R., Hossain M.S. Obesity, a major risk factor for immunity and severe outcomes of COVID-19. Biosci. Rep. 2021;41:BSR20210979. doi: 10.1042/BSR20210979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20210979</ArticleId><ArticleId IdType="pmc">PMC8380923</ArticleId><ArticleId IdType="pubmed">34350941</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J., Hlh Across Speciality Collaboration U.K. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033&#x2013;1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X. COVID-19: Immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020;20:269&#x2013;270. doi: 10.1038/s41577-020-0308-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0308-3</ArticleId><ArticleId IdType="pmc">PMC7143200</ArticleId><ArticleId IdType="pubmed">32273594</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D., Giles J.R., Baxter A.E., Oldridge D.A., Greenplate A.R., Wu J.E., Alanio C., Kuri-Cervantes L., Pampena M.B., D&#x2019;Andrea K., et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369:eabc8511. doi: 10.1126/science.abc8511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc8511</ArticleId><ArticleId IdType="pmc">PMC7402624</ArticleId><ArticleId IdType="pubmed">32669297</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez L., Pekkarinen P.T., Lakshmikanth T., Tan Z., Consiglio C.R., Pou C., Chen Y., Mugabo C.H., Nguyen N.A., Nowlan K., et al. Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19. Cell Rep. Med. 2020;1:100078. doi: 10.1016/j.xcrm.2020.100078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100078</ArticleId><ArticleId IdType="pmc">PMC7405891</ArticleId><ArticleId IdType="pubmed">32838342</ArticleId></ArticleIdList></Reference><Reference><Citation>Pairo-Castineira E., Clohisey S., Klaric L., Bretherick A.D., Rawlik K., Pasko D., Walker S., Parkinson N., Fourman M.H., Russell C.D., et al. Genetic mechanisms of critical illness in COVID-19. Nature. 2021;591:92&#x2013;98. doi: 10.1038/s41586-020-03065-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03065-y</ArticleId><ArticleId IdType="pubmed">33307546</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., Crooks M., Gabbay M., Brady M., Hishmeh L., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open. 2021;11:e048391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson J.F. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021;110:914&#x2013;921. doi: 10.1111/apa.15673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15673</ArticleId><ArticleId IdType="pmc">PMC7753397</ArticleId><ArticleId IdType="pubmed">33205450</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark D.V., Kibuuka H., Millard M., Wakabi S., Lukwago L., Taylor A., Eller M.A., Eller L.A., Michael N.L., Honko A.N., et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: A retrospective cohort study. Lancet Infect. Dis. 2015;15:905&#x2013;912. doi: 10.1016/S1473-3099(15)70152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)70152-0</ArticleId><ArticleId IdType="pubmed">25910637</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillot X., Ribera A., Gasque P. Chikungunya-Induced Arthritis in Reunion Island: A Long-Term Observational Follow-Up Study Showing Frequently Persistent Joint Symptoms, Some Cases of Persistent Chikungunya Immunoglobulin M Positivity, and No Anticyclic Citrullinated Peptide Seroconversion After 13 Years. J. Infect. Dis. 2020;222:1740&#x2013;1744. doi: 10.1093/infdis/jiaa261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa261</ArticleId><ArticleId IdType="pubmed">32428203</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I., Davenport T., Wakefield D., Vollmer-Conna U., Cameron B., Vernon S.D., Reeves W.C., Lloyd A., Dubbo Infection Outcomes Study G. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study. BMJ. 2006;333:575. doi: 10.1136/bmj.38933.585764.AE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.38933.585764.AE</ArticleId><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Osuchowski M.F., Winkler M.S., Skirecki T., Cajander S., Shankar-Hari M., Lachmann G., Monneret G., Venet F., Bauer M., Brunkhorst F.M., et al. The COVID-19 puzzle: Deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir. Med. 2021;9:622&#x2013;642. doi: 10.1016/S2213-2600(21)00218-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00218-6</ArticleId><ArticleId IdType="pmc">PMC8102044</ArticleId><ArticleId IdType="pubmed">33965003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley S.F., O&#x2019;Donnell D., Stoesser N.E., Matthews P.C., Howarth A., Hatch S.B., Marsden B.D., Cox S., James T., Warren F., et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N. Engl. J. Med. 2021;384:533&#x2013;540. doi: 10.1056/NEJMoa2034545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034545</ArticleId><ArticleId IdType="pmc">PMC7781098</ArticleId><ArticleId IdType="pubmed">33369366</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., Grifoni A., Ramirez S.I., Haupt S., Frazier A., et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371 doi: 10.1126/science.abf4063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen K.W., Linderman S.L., Moodie Z., Czartoski J., Lai L., Mantus G., Norwood C., Nyhoff L.E., Edara V.V., Floyd K., et al. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. medRxiv. 2021 doi: 10.1101/2021.04.19.21255739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.19.21255739</ArticleId><ArticleId IdType="pmc">PMC8253687</ArticleId><ArticleId IdType="pubmed">34250512</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Wang L., Schank M., Dang X., Lu Z., Cao D., Khanal S., Nguyen L.N., Nguyen L.N.T., Zhang J., et al. SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects. Virus Res. 2021;304:198508. doi: 10.1016/j.virusres.2021.198508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2021.198508</ArticleId><ArticleId IdType="pmc">PMC8314866</ArticleId><ArticleId IdType="pubmed">34329696</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Y.X., Ng Y.L., Tam J.P., Liu D.X. Human Coronaviruses: A Review of Virus-Host Interactions. Diseases. 2016;4:26. doi: 10.3390/diseases4030026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases4030026</ArticleId><ArticleId IdType="pmc">PMC5456285</ArticleId><ArticleId IdType="pubmed">28933406</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald K.A., Kagan J.C. Toll-like Receptors and the Control of Immunity. Cell. 2020;180:1044&#x2013;1066. doi: 10.1016/j.cell.2020.02.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.041</ArticleId><ArticleId IdType="pmc">PMC9358771</ArticleId><ArticleId IdType="pubmed">32164908</ArticleId></ArticleIdList></Reference><Reference><Citation>Nieto-Torres J.L., Verdia-Baguena C., Jimenez-Guardeno J.M., Regla-Nava J.A., Castano-Rodriguez C., Fernandez-Delgado R., Torres J., Aguilella V.M., Enjuanes L. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology. 2015;485:330&#x2013;339. doi: 10.1016/j.virol.2015.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2015.08.010</ArticleId><ArticleId IdType="pmc">PMC4619128</ArticleId><ArticleId IdType="pubmed">26331680</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues T.S., de Sa K.S.G., Ishimoto A.Y., Becerra A., Oliveira S., Almeida L., Goncalves A.V., Perucello D.B., Andrade W.A., Castro R., et al. Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J. Exp. Med. 2021;218 doi: 10.1084/jem.20201707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201707</ArticleId><ArticleId IdType="pmc">PMC7684031</ArticleId><ArticleId IdType="pubmed">33231615</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Lu W., Zhang Y., Zhang G., Shi X., Hisada Y., Grover S.P., Zhang X., Li L., Xiang B., et al. Inflammasome Activation Triggers Blood Clotting and Host Death through Pyroptosis. Immunity. 2019;50:1401&#x2013;1411. doi: 10.1016/j.immuni.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.04.003</ArticleId><ArticleId IdType="pmc">PMC6791531</ArticleId><ArticleId IdType="pubmed">31076358</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y., Zhang H., Mu S., Wei W., Jin C., Tong C., Song Z., Zha Y., Xue Y., Gu G. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: A retrospective and observational study. Aging. 2020;12:11245&#x2013;11258. doi: 10.18632/aging.103372.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103372</ArticleId><ArticleId IdType="pmc">PMC7343511</ArticleId><ArticleId IdType="pubmed">32633729</ArticleId></ArticleIdList></Reference><Reference><Citation>Zust R., Cervantes-Barragan L., Habjan M., Maier R., Neuman B.W., Ziebuhr J., Szretter K.J., Baker S.C., Barchet W., Diamond M.S., et al. Ribose 2&#x2032;-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat. Immunol. 2011;12:137&#x2013;143. doi: 10.1038/ni.1979.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1979</ArticleId><ArticleId IdType="pmc">PMC3182538</ArticleId><ArticleId IdType="pubmed">21217758</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel M., Pichlmair A., Martinez-Sobrido L., Cros J., Garcia-Sastre A., Haller O., Weber F. Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J. Virol. 2005;79:2079&#x2013;2086. doi: 10.1128/JVI.79.4.2079-2086.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.4.2079-2086.2005</ArticleId><ArticleId IdType="pmc">PMC546554</ArticleId><ArticleId IdType="pubmed">15681410</ArticleId></ArticleIdList></Reference><Reference><Citation>Miorin L., Kehrer T., Sanchez-Aparicio M.T., Zhang K., Cohen P., Patel R.S., Cupic A., Makio T., Mei M., Moreno E., et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc. Natl. Acad. Sci. USA. 2020;117:28344&#x2013;28354. doi: 10.1073/pnas.2016650117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2016650117</ArticleId><ArticleId IdType="pmc">PMC7668094</ArticleId><ArticleId IdType="pubmed">33097660</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam P.S., Wimmers F., Mok C.K.P., Perera R., Scott M., Hagan T., Sigal N., Feng Y., Bristow L., Tak-Yin Tsang O., et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369:1210&#x2013;1220. doi: 10.1126/science.abc6261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6261</ArticleId><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., Moller R., Jordan T.X., Oishi K., Panis M., Sachs D., et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036&#x2013;1045. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Vabret N., Britton G.J., Gruber C., Hegde S., Kim J., Kuksin M., Levantovsky R., Malle L., Moreira A., Park M.D., et al. Immunology of COVID-19: Current State of the Science. Immunity. 2020;52:910&#x2013;941. doi: 10.1016/j.immuni.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7200337</ArticleId><ArticleId IdType="pubmed">32505227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., Ogishi M., Sabli I.K.D., Hodeib S., Korol C., et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370 doi: 10.1126/science.abd4570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Levy R., Henriquez S., Bodemer C., Szwebel T.A., Casanova J.L. Interferon-beta Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2. J. Clin. Immunol. 2021;41:931&#x2013;933. doi: 10.1007/s10875-021-01023-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01023-5</ArticleId><ArticleId IdType="pmc">PMC7990897</ArticleId><ArticleId IdType="pubmed">33763778</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp S., Coppens M., van Haaps T.F., Foppen M., Vlaar A.P., Muller M.C.A., Bouman C.C.S., Beenen L.F.M., Kootte R.S., Heijmans J., et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J. Thromb. Haemost. 2020;18:1995&#x2013;2002. doi: 10.1111/jth.14888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14888</ArticleId><ArticleId IdType="pmc">PMC7497052</ArticleId><ArticleId IdType="pubmed">32369666</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudbjartsson D.F., Norddahl G.L., Melsted P., Gunnarsdottir K., Holm H., Eythorsson E., Arnthorsson A.O., Helgason D., Bjarnadottir K., Ingvarsson R.F., et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N. Engl. J. Med. 2020;383:1724&#x2013;1734. doi: 10.1056/NEJMoa2026116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2026116</ArticleId><ArticleId IdType="pmc">PMC7494247</ArticleId><ArticleId IdType="pubmed">32871063</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajnberg A., Amanat F., Firpo A., Altman D.R., Bailey M.J., Mansour M., McMahon M., Meade P., Mendu D.R., Muellers K., et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370:1227&#x2013;1230. doi: 10.1126/science.abd7728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd7728</ArticleId><ArticleId IdType="pmc">PMC7810037</ArticleId><ArticleId IdType="pubmed">33115920</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489&#x2013;1501. doi: 10.1016/j.cell.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetro J.A. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 2020;22:72&#x2013;73. doi: 10.1016/j.micinf.2020.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2020.02.006</ArticleId><ArticleId IdType="pmc">PMC7102551</ArticleId><ArticleId IdType="pubmed">32092539</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan Y., Shang J., Sun S., Tai W., Chen J., Geng Q., He L., Chen Y., Wu J., Shi Z., et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J. Virol. 2020;94:e02015-19. doi: 10.1128/JVI.02015-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02015-19</ArticleId><ArticleId IdType="pmc">PMC7022351</ArticleId><ArticleId IdType="pubmed">31826992</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861&#x2013;880. doi: 10.1016/j.cell.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D., Juno J.A., Khoury D., Reynaldi A., Wheatley A.K., Kent S.J., Davenport M.P. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 2021;21:395&#x2013;404. doi: 10.1038/s41577-021-00550-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00550-x</ArticleId><ArticleId IdType="pmc">PMC8082486</ArticleId><ArticleId IdType="pubmed">33927374</ArticleId></ArticleIdList></Reference><Reference><Citation>Smorenberg A., Peters E.J., van Daele P., Nossent E.J., Muller M. How does SARS-CoV-2 targets the elderly patients? A review on potential mechanisms increasing disease severity. Eur. J. Intern. Med. 2021;83:1&#x2013;5. doi: 10.1016/j.ejim.2020.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2020.11.024</ArticleId><ArticleId IdType="pmc">PMC7703548</ArticleId><ArticleId IdType="pubmed">33303345</ArticleId></ArticleIdList></Reference><Reference><Citation>Soiza R.L., Scicluna C., Thomson E.C. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021;50:279&#x2013;283. doi: 10.1093/ageing/afaa274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afaa274</ArticleId><ArticleId IdType="pmc">PMC7799251</ArticleId><ArticleId IdType="pubmed">33320183</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T., Ellingson M.K., Wong P., Israelow B., Lucas C., Klein J., Silva J., Mao T., Oh J.E., Tokuyama M., et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315&#x2013;320. doi: 10.1038/s41586-020-2700-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2700-3</ArticleId><ArticleId IdType="pmc">PMC7725931</ArticleId><ArticleId IdType="pubmed">32846427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowitdamrong E., Puthanakit T., Jantarabenjakul W., Prompetchara E., Suchartlikitwong P., Putcharoen O., Hirankarn N. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. PLoS ONE. 2020;15:e0240502. doi: 10.1371/journal.pone.0240502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240502</ArticleId><ArticleId IdType="pmc">PMC7546485</ArticleId><ArticleId IdType="pubmed">33035234</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisberg S.P., Connors T.J., Zhu Y., Baldwin M.R., Lin W.H., Wontakal S., Szabo P.A., Wells S.B., Dogra P., Gray J., et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat. Immunol. 2021;22:25&#x2013;31. doi: 10.1038/s41590-020-00826-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00826-9</ArticleId><ArticleId IdType="pmc">PMC8136619</ArticleId><ArticleId IdType="pubmed">33154590</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Guo X., Xin Q., Pan Y., Hu Y., Li J., Chu Y., Feng Y., Wang Q. Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients. Clin. Infect. Dis. 2020;71:2688&#x2013;2694. doi: 10.1093/cid/ciaa721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa721</ArticleId><ArticleId IdType="pmc">PMC7314147</ArticleId><ArticleId IdType="pubmed">32497196</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichler D., Baumgartner M., Kimpel J., Rossler A., Riepler L., Bates K., Fleischer V., von Laer D., Borena W., Wurzner R. Marked increase in avidity of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) antibodies 7-8 months after infection is not diminished in old age. J. Infect. Dis. 2021;224:764&#x2013;770. doi: 10.1093/infdis/jiab300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab300</ArticleId><ArticleId IdType="pmc">PMC8195195</ArticleId><ArticleId IdType="pubmed">34086960</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang D., Lian X., Song F., Ma H., Lian Z., Liang Y., Qin T., Chen W., Wang S. Clinical features of severe patients infected with 2019 novel coronavirus: A systematic review and meta-analysis. Ann. Transl. Med. 2020;8:576. doi: 10.21037/atm-20-2124.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-20-2124</ArticleId><ArticleId IdType="pmc">PMC7290556</ArticleId><ArticleId IdType="pubmed">32566603</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith J.C., Sausville E.L., Girish V., Yuan M.L., Vasudevan A., John K.M., Sheltzer J.M. Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract. Dev. Cell. 2020;53:514&#x2013;529. doi: 10.1016/j.devcel.2020.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2020.05.012</ArticleId><ArticleId IdType="pmc">PMC7229915</ArticleId><ArticleId IdType="pubmed">32425701</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagunas-Rangel F.A. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J. Med. Virol. 2020;92:1733&#x2013;1734. doi: 10.1002/jmv.25819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25819</ArticleId><ArticleId IdType="pmc">PMC7228336</ArticleId><ArticleId IdType="pubmed">32242950</ArticleId></ArticleIdList></Reference><Reference><Citation>Yilmaz H., Ucan B., Sayki M., Unsal I., Sahin M., Ozbek M., Delibasi T. Usefulness of the neutrophil-to-lymphocyte ratio to prediction of type 2 diabetes mellitus in morbid obesity. Diabetes Metab. Syndr. 2015;9:299&#x2013;304. doi: 10.1016/j.dsx.2014.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2014.04.009</ArticleId><ArticleId IdType="pubmed">25470646</ArticleId></ArticleIdList></Reference><Reference><Citation>Molony R.D., Nguyen J.T., Kong Y., Montgomery R.R., Shaw A.C., Iwasaki A. Aging impairs both primary and secondary RIG-I signaling for interferon induction in human monocytes. Sci. Signal. 2017;10 doi: 10.1126/scisignal.aan2392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aan2392</ArticleId><ArticleId IdType="pmc">PMC6429941</ArticleId><ArticleId IdType="pubmed">29233916</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D., Sharif K., O&#x2019;Regan A., Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun. Rev. 2020;19:102537. doi: 10.1016/j.autrev.2020.102537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102537</ArticleId><ArticleId IdType="pmc">PMC7195002</ArticleId><ArticleId IdType="pubmed">32251717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang R., Chen R., Zhang Q., Hou W., Wu S., Cao L., Huang J., Yu Y., Fan X.G., Yan Z., et al. HMGB1 in health and disease. Mol. Aspects Med. 2014;40:1&#x2013;116. doi: 10.1016/j.mam.2014.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2014.05.001</ArticleId><ArticleId IdType="pmc">PMC4254084</ArticleId><ArticleId IdType="pubmed">25010388</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin P. Why is COVID-19 so mild in children? Acta Paediatr. 2020;109:1082&#x2013;1083. doi: 10.1111/apa.15271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apa.15271</ArticleId><ArticleId IdType="pubmed">32212348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmann T.R., Levy O., Montgomery R.R., Goriely S. Innate immune function by Toll-like receptors: Distinct responses in newborns and the elderly. Immunity. 2012;37:771&#x2013;783. doi: 10.1016/j.immuni.2012.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.10.014</ArticleId><ArticleId IdType="pmc">PMC3538030</ArticleId><ArticleId IdType="pubmed">23159225</ArticleId></ArticleIdList></Reference><Reference><Citation>Saso A., Kampmann B. Vaccine responses in newborns. Semin. Immunopathol. 2017;39:627&#x2013;642. doi: 10.1007/s00281-017-0654-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0654-9</ArticleId><ArticleId IdType="pmc">PMC5711983</ArticleId><ArticleId IdType="pubmed">29124321</ArticleId></ArticleIdList></Reference><Reference><Citation>Torjesen I. Covid-19: Middle aged women face greater risk of debilitating long term symptoms. BMJ. 2021;372:n829. doi: 10.1136/bmj.n829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n829</ArticleId><ArticleId IdType="pubmed">33766927</ArticleId></ArticleIdList></Reference><Reference><Citation>Berghofer B., Frommer T., Haley G., Fink L., Bein G., Hackstein H. TLR7 ligands induce higher IFN-alpha production in females. J. Immunol. 2006;177:2088&#x2013;2096. doi: 10.4049/jimmunol.177.4.2088.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.4.2088</ArticleId><ArticleId IdType="pubmed">16887967</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein S.L., Jedlicka A., Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 2010;10:338&#x2013;349. doi: 10.1016/S1473-3099(10)70049-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70049-9</ArticleId><ArticleId IdType="pmc">PMC6467501</ArticleId><ArticleId IdType="pubmed">20417416</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb K., Peckham H., Radziszewska A., Menon M., Oliveri P., Simpson F., Deakin C.T., Lee S., Ciurtin C., Butler G., et al. Sex and Pubertal Differences in the Type 1 Interferon Pathway Associate With Both X Chromosome Number and Serum Sex Hormone Concentration. Front. Immunol. 2018;9:3167. doi: 10.3389/fimmu.2018.03167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.03167</ArticleId><ArticleId IdType="pmc">PMC6345344</ArticleId><ArticleId IdType="pubmed">30705679</ArticleId></ArticleIdList></Reference><Reference><Citation>Pido-Lopez J., Imami N., Aspinall R. Both age and gender affect thymic output: More recent thymic migrants in females than males as they age. Clin. Exp. Immunol. 2001;125:409&#x2013;413. doi: 10.1046/j.1365-2249.2001.01640.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.2001.01640.x</ArticleId><ArticleId IdType="pmc">PMC1906152</ArticleId><ArticleId IdType="pubmed">11531948</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker E., Bamford A., Kenny J., Kaforou M., Jones C.E., Shah P., Ramnarayan P., Fraisse A., Miller O., Davies P., et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA. 2020;324:259&#x2013;269. doi: 10.1001/jama.2020.10369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.10369</ArticleId><ArticleId IdType="pmc">PMC7281356</ArticleId><ArticleId IdType="pubmed">32511692</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulendran B., Li S., Nakaya H.I. Systems vaccinology. Immunity. 2010;33:516&#x2013;529. doi: 10.1016/j.immuni.2010.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2010.10.006</ArticleId><ArticleId IdType="pmc">PMC3001343</ArticleId><ArticleId IdType="pubmed">21029962</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Chen Y., Liu M., Shi S., Tian J. Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. J. Infect. 2020;81:e93&#x2013;e95. doi: 10.1016/j.jinf.2020.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.05.017</ArticleId><ArticleId IdType="pmc">PMC7228685</ArticleId><ArticleId IdType="pubmed">32417309</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung M., Babik J.M. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin. Infect. Dis. 2021;72:340&#x2013;350. doi: 10.1093/cid/ciaa863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa863</ArticleId><ArticleId IdType="pmc">PMC7337668</ArticleId><ArticleId IdType="pubmed">33501974</ArticleId></ArticleIdList></Reference><Reference><Citation>Robilotti E.V., Babady N.E., Mead P.A., Rolling T., Perez-Johnston R., Bernardes M., Bogler Y., Caldararo M., Figueroa C.J., Glickman M.S., et al. Determinants of COVID-19 disease severity in patients with cancer. Nat. Med. 2020;26:1218&#x2013;1223. doi: 10.1038/s41591-020-0979-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0979-0</ArticleId><ArticleId IdType="pmc">PMC7785283</ArticleId><ArticleId IdType="pubmed">32581323</ArticleId></ArticleIdList></Reference><Reference><Citation>Challenor S., Tucker D. SARS-CoV-2-induced remission of Hodgkin lymphoma. Br. J. Haematol. 2021;192:415. doi: 10.1111/bjh.17116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17116</ArticleId><ArticleId IdType="pubmed">33386647</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner T.W., Dunphy C., Fedoriw Y.D., van Deventer H.W., Foster M.C., Richards K.L., Park S.I. Complete spontaneous remission of diffuse large B-cell lymphoma of the maxillary sinus after concurrent infections. Clin. Lymphoma Myeloma Leuk. 2012;12:455&#x2013;458. doi: 10.1016/j.clml.2012.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2012.06.007</ArticleId><ArticleId IdType="pubmed">23025990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahraman S., Akinci M.B., Sendur M.A.N., Yalcin B. Can the host immune response against SARS-CoV2 also cause an anticancer effect? Med. Oncol. 2021;38:90. doi: 10.1007/s12032-021-01533-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12032-021-01533-7</ArticleId><ArticleId IdType="pmc">PMC8243040</ArticleId><ArticleId IdType="pubmed">34191146</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonani B., Aslam F., Goyal A., Patel J., Bansal P. COVID-19 vaccination in immunocompromised patients. Clin. Rheumatol. 2021;40:797&#x2013;798. doi: 10.1007/s10067-020-05547-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05547-w</ArticleId><ArticleId IdType="pmc">PMC7797352</ArticleId><ArticleId IdType="pubmed">33426632</ArticleId></ArticleIdList></Reference><Reference><Citation>Openshaw P.J.M., Chiu C., Culley F.J., Johansson C. Protective and Harmful Immunity to RSV Infection. Annu. Rev. Immunol. 2017;35:501&#x2013;532. doi: 10.1146/annurev-immunol-051116-052206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-051116-052206</ArticleId><ArticleId IdType="pubmed">28226227</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassaniti I., Percivalle E., Bergami F., Piralla A., Comolli G., Bruno R., Vecchia M., Sambo M., Colaneri M., Zuccaro V., et al. SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay. Clin. Microbiol. Infect. 2021;27:1029&#x2013;1034. doi: 10.1016/j.cmi.2021.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.03.010</ArticleId><ArticleId IdType="pmc">PMC8016542</ArticleId><ArticleId IdType="pubmed">33813122</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Liu X., Zhang X., Lin Y., Liu D., Xun J., Wang Z., Gu L., Li Q., Yin D., et al. Decline in neutralising antibody responses, but sustained T-cell immunity, in COVID-19 patients at 7 months post-infection. Clin. Transl. Immunol. 2021;10:e1319. doi: 10.1002/cti2.1319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1319</ArticleId><ArticleId IdType="pmc">PMC8313961</ArticleId><ArticleId IdType="pubmed">34336207</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacius A., Tischer-Zimmermann S., Dragon A.C., Gussarow D., Vogel A., Krettek U., Godecke N., Yilmaz M., Kraft A.R.M., Hoeper M.M., et al. COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses. Immunity. 2021;54:340&#x2013;354. doi: 10.1016/j.immuni.2021.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.01.008</ArticleId><ArticleId IdType="pmc">PMC7871825</ArticleId><ArticleId IdType="pubmed">33567252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangge H., Pruller F., Schnedl W., Renner W., Almer G. Beyond Macrophages and T Cells: B Cells and Immunoglobulins Determine the Fate of the Atherosclerotic Plaque. Int. J. Mol. Sci. 2020;21:4082. doi: 10.3390/ijms21114082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21114082</ArticleId><ArticleId IdType="pmc">PMC7312004</ArticleId><ArticleId IdType="pubmed">32521607</ArticleId></ArticleIdList></Reference><Reference><Citation>Seow J., Graham C., Merrick B., Acors S., Pickering S., Steel K.J.A., Hemmings O., O&#x2019;Byrne A., Kouphou N., Galao R.P., et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 2020;5:1598&#x2013;1607. doi: 10.1038/s41564-020-00813-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00813-8</ArticleId><ArticleId IdType="pmc">PMC7610833</ArticleId><ArticleId IdType="pubmed">33106674</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagioti E., Klenerman P., Lee L.N., van der Burg S.H., Arens R. Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections. Front. Immunol. 2018;9:276. doi: 10.3389/fimmu.2018.00276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00276</ArticleId><ArticleId IdType="pmc">PMC5820320</ArticleId><ArticleId IdType="pubmed">29503649</ArticleId></ArticleIdList></Reference><Reference><Citation>Prendecki M., Clarke C., Edwards H., McIntyre S., Mortimer P., Gleeson S., Martin P., Thomson T., Randell P., Shah A., et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann. Rheum. Dis. 2021;80:1322&#x2013;1329. doi: 10.1136/annrheumdis-2021-220626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220626</ArticleId><ArticleId IdType="pmc">PMC8350975</ArticleId><ArticleId IdType="pubmed">34362747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahil S.K., Bechman K., Raharja A., Domingo-Vila C., Baudry D., Brown M.A., Cope A.P., Dasandi T., Graham C., Lechmere T., et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: A cohort study. Lancet Rheumatol. 2021;3:e627&#x2013;e637. doi: 10.1016/S2665-9913(21)00212-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00212-5</ArticleId><ArticleId IdType="pmc">PMC8266273</ArticleId><ArticleId IdType="pubmed">34258590</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhang L., Sang L., Ye F., Ruan S., Zhong B., Song T., Alshukairi A.N., Chen R., Zhang Z., et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J. Clin. Investig. 2020;130:5235&#x2013;5244. doi: 10.1172/JCI138759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138759</ArticleId><ArticleId IdType="pmc">PMC7524490</ArticleId><ArticleId IdType="pubmed">32634129</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockstroh A., Wolf J., Fertey J., Kalbitz S., Schroth S., Lubbert C., Ulbert S., Borte S. Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort. Emerg. Microbes Infect. 2021;10:774&#x2013;781. doi: 10.1080/22221751.2021.1913973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1913973</ArticleId><ArticleId IdType="pmc">PMC8079054</ArticleId><ArticleId IdType="pubmed">33830901</ArticleId></ArticleIdList></Reference><Reference><Citation>Trenti T., Pecoraro V., Pirotti T., Plebani M. IgM anti-SARS-CoV-2-specific determination: Useful or confusing? Big Data analysis of a real-life scenario. Intern. Emerg. Med. 1007:1&#x2013;4. doi: 10.1007/s11739-021-02747-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-021-02747-3</ArticleId><ArticleId IdType="pmc">PMC8088482</ArticleId><ArticleId IdType="pubmed">33934298</ArticleId></ArticleIdList></Reference><Reference><Citation>Azkur A.K., Akdis M., Azkur D., Sokolowska M., van de Veen W., Bruggen M.C., O&#x2019;Mahony L., Gao Y., Nadeau K., Akdis C.A. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564&#x2013;1581. doi: 10.1111/all.14364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14364</ArticleId><ArticleId IdType="pmc">PMC7272948</ArticleId><ArticleId IdType="pubmed">32396996</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav A.K., Ghosh S., Dubey S. Conundrum of re-positive COVID-19 cases: A systematic review of case reports and case series. Med. J. Armed Forces India. 2021;77:S413&#x2013;S423. doi: 10.1016/j.mjafi.2021.05.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mjafi.2021.05.025</ArticleId><ArticleId IdType="pmc">PMC8313065</ArticleId><ArticleId IdType="pubmed">34334911</ArticleId></ArticleIdList></Reference><Reference><Citation>Murillo-Zamora E., Mendoza-Cano O., Delgado-Enciso I., Hernandez-Suarez C.M. Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection. Public Health. 2021;193:113&#x2013;115. doi: 10.1016/j.puhe.2021.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2021.01.021</ArticleId><ArticleId IdType="pmc">PMC7879028</ArticleId><ArticleId IdType="pubmed">33774512</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto L.M., Nanda V., Sunavala A., Rodriques C. Reinfection in COVID-19: A scoping review. Med. J. Armed Forces India. 2021;77:S257&#x2013;S263. doi: 10.1016/j.mjafi.2021.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mjafi.2021.02.010</ArticleId><ArticleId IdType="pmc">PMC8313064</ArticleId><ArticleId IdType="pubmed">34334891</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh E.E., Frenck R.W., Jr., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N. Engl. J. Med. 2020;383:2439&#x2013;2450. doi: 10.1056/NEJMoa2027906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467&#x2013;478. doi: 10.1016/S0140-6736(20)31604-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31604-4</ArticleId><ArticleId IdType="pmc">PMC7445431</ArticleId><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasireddy D., Vanaparthy R., Mohan G., Malayala S.V., Atluri P. Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know? J. Clin. Med. Res. 2021;13:317&#x2013;325. doi: 10.14740/jocmr4518.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr4518</ArticleId><ArticleId IdType="pmc">PMC8256910</ArticleId><ArticleId IdType="pubmed">34267839</ArticleId></ArticleIdList></Reference><Reference><Citation>Alturaiki W., Mubarak A., Al Jurayyan A., Hemida M.G. The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2. Hum. Vaccines Immunother. 2021:1&#x2013;13. doi: 10.1080/21645515.2021.1935172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.1935172</ArticleId><ArticleId IdType="pmc">PMC8204314</ArticleId><ArticleId IdType="pubmed">34114940</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann D.M., Boyton R.J., Beale R. Immunity to SARS-CoV-2 variants of concern. Science. 2021;371:1103&#x2013;1104. doi: 10.1126/science.abg7404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg7404</ArticleId><ArticleId IdType="pubmed">33707254</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N., Tan A.T., Kunasegaran K., Tham C.Y.L., Hafezi M., Chia A., Chng M.H.Y., Lin M., Tan N., Linster M., et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457&#x2013;462. doi: 10.1038/s41586-020-2550-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2550-z</ArticleId><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelde A., Bilich T., Heitmann J.S., Maringer Y., Salih H.R., Roerden M., Lubke M., Bauer J., Rieth J., Wacker M., et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 2021;22:74&#x2013;85. doi: 10.1038/s41590-020-00808-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00808-x</ArticleId><ArticleId IdType="pubmed">32999467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng K.W., Faulkner N., Cornish G.H., Rosa A., Harvey R., Hussain S., Ulferts R., Earl C., Wrobel A.G., Benton D.J., et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370:1339&#x2013;1343. doi: 10.1126/science.abe1107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe1107</ArticleId><ArticleId IdType="pmc">PMC7857411</ArticleId><ArticleId IdType="pubmed">33159009</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal N., Garg R., Singh S., Agrawal A. Coronavirus disease 2019 in pregnancy: Maternal and perinatal outcome. J. Educ. Health Promot. 2021;10:194. doi: 10.4103/jehp.jehp_954_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jehp.jehp_954_20</ArticleId><ArticleId IdType="pmc">PMC8249977</ArticleId><ArticleId IdType="pubmed">34250128</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums D.V. Editorial: Maternal SARS-CoV-2 Infection and Pregnancy Outcomes from Current Global Study Data. Med. Sci. Monit. 2021;27:e933831. doi: 10.12659/MSM.933831.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.933831</ArticleId><ArticleId IdType="pmc">PMC8268975</ArticleId><ArticleId IdType="pubmed">34219126</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookstein Peretz S., Regev N., Novick L., Nachshol M., Goffer E., Ben-David A., Asraf K., Doolman R., Sapir E., Regev Yochay G., et al. Short-term outcome of pregnant women vaccinated by BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obstet. Gynecol. 2021;58:450&#x2013;456. doi: 10.1002/uog.23729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/uog.23729</ArticleId><ArticleId IdType="pmc">PMC8441755</ArticleId><ArticleId IdType="pubmed">34198360</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz D.A. An Analysis of 38 Pregnant Women With COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes. Arch. Pathol. Lab. Med. 2020;144:799&#x2013;805. doi: 10.5858/arpa.2020-0901-SA.</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2020-0901-SA</ArticleId><ArticleId IdType="pubmed">32180426</ArticleId></ArticleIdList></Reference><Reference><Citation>Juan J., Gil M.M., Rong Z., Zhang Y., Yang H., Poon L.C. Effect of coronavirus disease 2019 (COVID-19) on maternal, perinatal and neonatal outcome: Systematic review. Ultrasound Obstet. Gynecol. 2020;56:15&#x2013;27. doi: 10.1002/uog.22088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/uog.22088</ArticleId><ArticleId IdType="pmc">PMC7276742</ArticleId><ArticleId IdType="pubmed">32430957</ArticleId></ArticleIdList></Reference><Reference><Citation>Wastnedge E.A.N., Reynolds R.M., van Boeckel S.R., Stock S.J., Denison F.C., Maybin J.A., Critchley H.O.D. Pregnancy and COVID-19. Physiol. Rev. 2021;101:303&#x2013;318. doi: 10.1152/physrev.00024.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00024.2020</ArticleId><ArticleId IdType="pmc">PMC7686875</ArticleId><ArticleId IdType="pubmed">32969772</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapolla A., Dalfra M.G., Burlina S. Vaccination against COVID-19 infection: The need of evidence for diabetic and obese pregnant women. Acta Diabetol. 2021 doi: 10.1007/s00592-021-01764-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-021-01764-0</ArticleId><ArticleId IdType="pmc">PMC8236746</ArticleId><ArticleId IdType="pubmed">34181082</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannery D.D., Gouma S., Dhudasia M.B., Mukhopadhyay S., Pfeifer M.R., Woodford E.C., Triebwasser J.E., Gerber J.S., Morris J.S., Weirick M.E., et al. Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios. JAMA Pediatr. 2021;175:594&#x2013;600. doi: 10.1001/jamapediatrics.2021.0038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2021.0038</ArticleId><ArticleId IdType="pmc">PMC7846944</ArticleId><ArticleId IdType="pubmed">33512440</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz F.M. Can We Protect Pregnant Women and Young Infants From COVID-19 Through Maternal Immunization? JAMA Pediatr. 2021;175:561&#x2013;562. doi: 10.1001/jamapediatrics.2021.0043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2021.0043</ArticleId><ArticleId IdType="pubmed">33512398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee P.Y., Day-Lewis M., Henderson L.A., Friedman K.G., Lo J., Roberts J.E., Lo M.S., Platt C.D., Chou J., Hoyt K.J., et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J. Clin. Investig. 2020;130:5942&#x2013;5950. doi: 10.1172/JCI141113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI141113</ArticleId><ArticleId IdType="pmc">PMC7598077</ArticleId><ArticleId IdType="pubmed">32701511</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsaied T., Tremoulet A.H., Burns J.C., Saidi A., Dionne A., Lang S.M., Newburger J.W., de Ferranti S., Friedman K.G. Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children. Circulation. 2021;143:78&#x2013;88. doi: 10.1161/CIRCULATIONAHA.120.049836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.049836</ArticleId><ArticleId IdType="pubmed">33166178</ArticleId></ArticleIdList></Reference><Reference><Citation>Reveille J.D., Moulds J.M., Ahn C., Friedman A.W., Baethge B., Roseman J., Straaton K.V., Alarcon G.S. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum. 1998;41:1161&#x2013;1172. doi: 10.1002/1529-0131(199807)41:7&lt;1161::AID-ART4&gt;3.0.CO;2-K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199807)41:7&lt;1161::AID-ART4&gt;3.0.CO;2-K</ArticleId><ArticleId IdType="pubmed">9663471</ArticleId></ArticleIdList></Reference><Reference><Citation>Douglas J.A., Subica A.M. COVID-19 treatment resource disparities and social disadvantage in New York City. Prev. Med. 2020;141:106282. doi: 10.1016/j.ypmed.2020.106282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2020.106282</ArticleId><ArticleId IdType="pmc">PMC7536513</ArticleId><ArticleId IdType="pubmed">33035550</ArticleId></ArticleIdList></Reference><Reference><Citation>Consiglio C.R., Cotugno N., Sardh F., Pou C., Amodio D., Rodriguez L., Tan Z., Zicari S., Ruggiero A., Pascucci G.R., et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183:968&#x2013;981. doi: 10.1016/j.cell.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7474869</ArticleId><ArticleId IdType="pubmed">32966765</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushik A., Gupta S., Sood M., Sharma S., Verma S. A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 Infection. Pediatr. Infect. Dis. J. 2020;39:e340&#x2013;e346. doi: 10.1097/INF.0000000000002888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000002888</ArticleId><ArticleId IdType="pubmed">32925547</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Perez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99&#x2013;111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw R.H., Stuart A., Greenland M., Liu X., Van-Tam J.S.N., Snape M.D., Com C.O.V.S.G. Heterologous prime-boost COVID-19 vaccination: Initial reactogenicity data. Lancet. 2021;397:2043&#x2013;2046. doi: 10.1016/S0140-6736(21)01115-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01115-6</ArticleId><ArticleId IdType="pmc">PMC8115940</ArticleId><ArticleId IdType="pubmed">33991480</ArticleId></ArticleIdList></Reference><Reference><Citation>Powell A.A., Power L., Westrop S., McOwat K., Campbell H., Simmons R., Ramsay M.E., Brown K., Ladhani S.N., Amirthalingam G. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England. Eurosurveillance. 2021;26 doi: 10.2807/1560-7917.ES.2021.26.28.2100634.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.28.2100634</ArticleId><ArticleId IdType="pmc">PMC8284043</ArticleId><ArticleId IdType="pubmed">34269172</ArticleId></ArticleIdList></Reference><Reference><Citation>Borobia A.M., Carcas A.J., Perez-Olmeda M., Castano L., Bertran M.J., Garcia-Perez J., Campins M., Portoles A., Gonzalez-Perez M., Garcia Morales M.T., et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121&#x2013;130. doi: 10.1016/S0140-6736(21)01420-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01420-3</ArticleId><ArticleId IdType="pmc">PMC8233007</ArticleId><ArticleId IdType="pubmed">34181880</ArticleId></ArticleIdList></Reference><Reference><Citation>Canton R., De Lucas Ramos P., Garcia-Botella A., Garcia-Lledo A., Gomez-Pavon J., Gonzalez Del Castillo J., Hernandez-Sampelayo T., Martin-Delgado M.C., Martin Sanchez F.J., Martinez-Selles M., et al. New variants of SARS-CoV-2. Rev. Esp. Quimioter. 2021 doi: 10.37201/req/071.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.37201/req/071.2021</ArticleId><ArticleId IdType="pmc">PMC8638835</ArticleId><ArticleId IdType="pubmed">34076402</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi M., Shayestehpour M., Mirzaei H. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Braz. J. Infect. Dis. 2021;25:101606. doi: 10.1016/j.bjid.2021.101606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjid.2021.101606</ArticleId><ArticleId IdType="pmc">PMC8367756</ArticleId><ArticleId IdType="pubmed">34428473</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen S.A., Kelley C.F., Horton J.P., Jamieson D.J. Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: What Obstetricians Need to Know. Obstet. Gynecol. 2021;137:408&#x2013;414. doi: 10.1097/AOG.0000000000004290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000004290</ArticleId><ArticleId IdType="pmc">PMC7884084</ArticleId><ArticleId IdType="pubmed">33370015</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi H.K., Libby P., Ridker P.M. COVID-19&#x2014;A vascular disease. Trends Cardiovasc. Med. 2021;31:1&#x2013;5. doi: 10.1016/j.tcm.2020.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2020.10.005</ArticleId><ArticleId IdType="pmc">PMC7556303</ArticleId><ArticleId IdType="pubmed">33068723</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleksova A., Gagno G., Sinagra G., Beltrami A.P., Janjusevic M., Ippolito G., Zumla A., Fluca A.L., Ferro F. Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review. Int. J. Mol. Sci. 2021;22:4526. doi: 10.3390/ijms22094526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094526</ArticleId><ArticleId IdType="pmc">PMC8123609</ArticleId><ArticleId IdType="pubmed">33926110</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L., Benigni A., Casiraghi F., Ng L.F.P., Renia L., Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat. Rev. Nephrol. 2021;17:46&#x2013;64. doi: 10.1038/s41581-020-00357-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-020-00357-4</ArticleId><ArticleId IdType="pmc">PMC7570423</ArticleId><ArticleId IdType="pubmed">33077917</ArticleId></ArticleIdList></Reference><Reference><Citation>Drakos S., Chatzantonis G., Bietenbeck M., Evers G., Schulze A.B., Mohr M., Fonfara H., Meier C., Yilmaz A. A cardiovascular magnetic resonance imaging-based pilot study to assess coronary microvascular disease in COVID-19 patients. Sci. Rep. 2021;11:15667. doi: 10.1038/s41598-021-95277-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95277-z</ArticleId><ArticleId IdType="pmc">PMC8329060</ArticleId><ArticleId IdType="pubmed">34341436</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Z., Liu F., Blair R., Wang C., Yang H., Mudd J., Currey J.M., Iwanaga N., He J., Mi R., et al. Endothelial cell infection and dysfunction, immune activation in severe COVID-19. Theranostics. 2021;11:8076&#x2013;8091. doi: 10.7150/thno.61810.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.61810</ArticleId><ArticleId IdType="pmc">PMC8315069</ArticleId><ArticleId IdType="pubmed">34335981</ArticleId></ArticleIdList></Reference><Reference><Citation>Price L.C., Ridge C., Wells A.U. Pulmonary vascular involvement in COVID-19 pneumonitis: Is this the first and final insult? Respirology. 2021;26:832&#x2013;834. doi: 10.1111/resp.14123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/resp.14123</ArticleId><ArticleId IdType="pmc">PMC8446977</ArticleId><ArticleId IdType="pubmed">34322959</ArticleId></ArticleIdList></Reference><Reference><Citation>Eslamifar Z., Behzadifard M., Soleimani M., Behzadifard S. Coagulation abnormalities in SARS-CoV-2 infection: Overexpression tissue factor. Thromb. J. 2020;18:38. doi: 10.1186/s12959-020-00250-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-020-00250-x</ArticleId><ArticleId IdType="pmc">PMC7737414</ArticleId><ArticleId IdType="pubmed">33323111</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Rojas R.M., P&#xe9;rez-Rus G., Delgado-Pinos V.E., Domingo-Gonz&#xe1;lez A., Regalado-Artamendi I., Alba-Urdiales N., Demelo-Rodr&#xed;guez P., Monsalvo S., Rodr&#xed;guez-Mac&#xed;as G., Ballesteros M., et al. COVID-19 coagulopathy: An in-depth analysis of the coagulation system. Eur. J. Haematol. 2020;105:741&#x2013;750. doi: 10.1111/ejh.13501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13501</ArticleId><ArticleId IdType="pmc">PMC7436538</ArticleId><ArticleId IdType="pubmed">32749010</ArticleId></ArticleIdList></Reference><Reference><Citation>Gando S., Wada T. Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. Front. Immunol. 2021;12:649122. doi: 10.3389/fimmu.2021.649122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.649122</ArticleId><ArticleId IdType="pmc">PMC8226122</ArticleId><ArticleId IdType="pubmed">34177896</ArticleId></ArticleIdList></Reference><Reference><Citation>Neshin S.A.S., Shahjouei S., Koza E., Friedenberg I., Khodadadi F., Sabra M., Kobeissy F., Ansari S., Tsivgoulis G., Li J., et al. Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology. Front. Cardiovasc. Med. 2021;8:649922. doi: 10.3389/fcvm.2021.649922.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.649922</ArticleId><ArticleId IdType="pmc">PMC8039152</ArticleId><ArticleId IdType="pubmed">33855053</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman N., Antoniak S., Wolberg A.S., Kasthuri R., Key N.S. Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses. Arterioscler. Thromb. Vasc. Biol. 2020;40:2033&#x2013;2044. doi: 10.1161/ATVBAHA.120.314514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.314514</ArticleId><ArticleId IdType="pmc">PMC7447001</ArticleId><ArticleId IdType="pubmed">32657623</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahyavi-Firouz-Abadi N., Naik R.P. Cerebral venous sinus thrombosis associated with vaccine-induced thrombotic thrombocytopenia. Neuroradiol. J. 2021:19714009211036687. doi: 10.1177/19714009211036687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/19714009211036687</ArticleId><ArticleId IdType="pmc">PMC9130610</ArticleId><ArticleId IdType="pubmed">34333995</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz N.H., Sorvoll I.H., Michelsen A.E., Munthe L.A., Lund-Johansen F., Ahlen M.T., Wiedmann M., Aamodt A.H., Skattor T.H., Tjonnfjord G.E., et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 2021;384:2124&#x2013;2130. doi: 10.1056/NEJMoa2104882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104882</ArticleId><ArticleId IdType="pmc">PMC8112568</ArticleId><ArticleId IdType="pubmed">33835768</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med. 2021;384:2092&#x2013;2101. doi: 10.1056/NEJMoa2104840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2104840</ArticleId><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. AstraZeneca vaccine: Blood clots are "extremely rare" and benefits outweigh risks, regulators conclude. BMJ. 2021;373:n931. doi: 10.1136/bmj.n931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n931</ArticleId><ArticleId IdType="pubmed">33832929</ArticleId></ArticleIdList></Reference><Reference><Citation>Saposnik G., Barinagarrementeria F., Brown R.D., Jr., Bushnell C.D., Cucchiara B., Cushman M., deVeber G., Ferro J.M., Tsai F.Y., American Heart Association Stroke C., et al. Diagnosis and management of cerebral venous thrombosis: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:1158&#x2013;1192. doi: 10.1161/STR.0b013e31820a8364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STR.0b013e31820a8364</ArticleId><ArticleId IdType="pubmed">21293023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro J.M., Canhao P., Stam J., Bousser M.G., Barinagarrementeria F., Investigators I. Prognosis of cerebral vein and dural sinus thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) Stroke. 2004;35:664&#x2013;670. doi: 10.1161/01.STR.0000117571.76197.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.0000117571.76197.26</ArticleId><ArticleId IdType="pubmed">14976332</ArticleId></ArticleIdList></Reference><Reference><Citation>See I., Su J.R., Lale A., Woo E.J., Guh A.Y., Shimabukuro T.T., Streiff M.B., Rao A.K., Wheeler A.P., Beavers S.F., et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA. 2021;325:2448&#x2013;2456. doi: 10.1001/jama.2021.7517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.7517</ArticleId><ArticleId IdType="pmc">PMC8087975</ArticleId><ArticleId IdType="pubmed">33929487</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldenburg J., Klamroth R., Langer F., Albisetti M., von Auer C., Ay C., Korte W., Scharf R.E., P&#xf6;tzsch B., Greinacher A. Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH. H&#xe4;mostaseologie. 2021;41:184&#x2013;189. doi: 10.1055/a-1469-7481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1469-7481</ArticleId><ArticleId IdType="pubmed">33822348</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattringer T., Gressenberger P., Gary T., Wolfler A., Kneihsl M., Raggam R.B. Successful management of vaccine-induced immune thrombotic thrombocytopenia-related cerebral sinus venous thrombosis after ChAdOx1 nCov-19 vaccination. Stroke Vasc. Neurol. 2021 doi: 10.1136/svn-2021-001142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/svn-2021-001142</ArticleId><ArticleId IdType="pmc">PMC8899650</ArticleId><ArticleId IdType="pubmed">34244449</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie K.L., Cushman M., Elkind M.S.V., Lyden P.D., Saposnik G., American Heart Association/American Stroke Association Stroke Council Leadership Diagnosis and Management of Cerebral Venous Sinus Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia. Stroke. 2021;52:2478&#x2013;2482. doi: 10.1161/STROKEAHA.121.035564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.121.035564</ArticleId><ArticleId IdType="pubmed">33914590</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M., Singh D., Lown R., Poles A., Solomon T., Levi M., Goldblatt D., Kotoucek P., Thomas W., Lester W. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 2021;384:2202&#x2013;2211. doi: 10.1056/NEJMoa2105385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105385</ArticleId><ArticleId IdType="pmc">PMC8112532</ArticleId><ArticleId IdType="pubmed">33861525</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson E.J., Rouphael N.G., Widge A.T., Jackson L.A., Roberts P.C., Makhene M., Chappell J.D., Denison M.R., Stevens L.J., Pruijssers A.J., et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N. Engl. J. Med. 2020;383:2427&#x2013;2438. doi: 10.1056/NEJMoa2028436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028436</ArticleId><ArticleId IdType="pmc">PMC7556339</ArticleId><ArticleId IdType="pubmed">32991794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy M.N., Minassian A.M., Ewer K.J., Flaxman A.L., Folegatti P.M., Owens D.R., Voysey M., Aley P.K., Angus B., Babbage G., et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979&#x2013;1993. doi: 10.1016/S0140-6736(20)32466-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32466-1</ArticleId><ArticleId IdType="pmc">PMC7674972</ArticleId><ArticleId IdType="pubmed">33220855</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegu A., O&#x2019;Connell S., Schmidt S.D., O&#x2019;Dell S., Talana C.A., Lai L., Albert J., Anderson E., Bennett H., Corbett K.S., et al. Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants. bioRxiv. 2021 doi: 10.1101/2021.05.13.444010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.13.444010</ArticleId><ArticleId IdType="pmc">PMC8691522</ArticleId><ArticleId IdType="pubmed">34385356</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y., Zhong L., Tan J., Zhang Z., Lyu J., Chen Y., Zhao A., Huang L., Long Z., Liu N.-N., et al. How to Understand &#x201c;Herd Immunity&#x201d; in COVID-19 Pandemic. Front. Cell Dev. Biol. 2020;8:547314. doi: 10.3389/fcell.2020.547314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.547314</ArticleId><ArticleId IdType="pmc">PMC7543944</ArticleId><ArticleId IdType="pubmed">33072741</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson R.M., Vegvari C., Truscott J., Collyer B.S. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet. 2020;396:1614&#x2013;1616. doi: 10.1016/S0140-6736(20)32318-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32318-7</ArticleId><ArticleId IdType="pmc">PMC7836302</ArticleId><ArticleId IdType="pubmed">33159850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok K.O., McNeil E.B., Tsoi M.T.F., Wei V.W.I., Wong S.Y.S., Tang J.W.T. Will achieving herd immunity be a road to success to end the COVID-19 pandemic? J. Infect. 2021;83:381&#x2013;412. doi: 10.1016/j.jinf.2021.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.06.007</ArticleId><ArticleId IdType="pmc">PMC8189733</ArticleId><ArticleId IdType="pubmed">34118274</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Zhang J., Cai J., Deng X., Peng C., Chen X., Yang J., Wu Q., Chen Z., Zheng W., et al. Herd immunity induced by COVID-19 vaccination programs to suppress epidemics caused by SARS-CoV-2 wild type and variants in China. medRxiv. 2021 doi: 10.1101/2021.07.23.21261013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.23.21261013</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer O. Covid-19: Delta infections threaten herd immunity vaccine strategy. BMJ. 2021;374:n1933. doi: 10.1136/bmj.n1933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1933</ArticleId><ArticleId IdType="pubmed">34340962</ArticleId></ArticleIdList></Reference><Reference><Citation>Cihan P. Forecasting fully vaccinated people against COVID-19 and examining future vaccination rate for herd immunity in the US, Asia, Europe, Africa, South America, and the World. Appl. Soft Comput. 2021;111:107708. doi: 10.1016/j.asoc.2021.107708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.asoc.2021.107708</ArticleId><ArticleId IdType="pmc">PMC8278839</ArticleId><ArticleId IdType="pubmed">34305491</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham F. Daily briefing: Coronavirus outbreaks in France and Spain show we&#x2019;re nowhere near herd immunity. Nature. 2020 doi: 10.1038/d41586-020-01460-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-01460-z</ArticleId><ArticleId IdType="pubmed">33986500</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahambing J.G. Radicalizing moral conservatism in herd immunity during COVID-19. J. Public Health. 2021:fdab307. doi: 10.1093/pubmed/fdab307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pubmed/fdab307</ArticleId><ArticleId IdType="pubmed">34297131</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma N., Vyas S., Mohapatra A., Khanduri R., Roy P., Kumar R. Combating COVID-19 pandemic in India: Demystifying the concept of herd immunity. J. Fam. Med. Prim. Care. 2021;10:1515&#x2013;1519. doi: 10.4103/jfmpc.jfmpc_1971_20.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jfmpc.jfmpc_1971_20</ArticleId><ArticleId IdType="pmc">PMC8144793</ArticleId><ArticleId IdType="pubmed">34123884</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan N.A. The road to addressing Long Covid. Science. 2021;373:491&#x2013;493. doi: 10.1126/science.abg7113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg7113</ArticleId><ArticleId IdType="pubmed">34326224</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra P.K., Bruiners N., Ukey R., Datta P., Onyuka A., Handler D., Hussain S., Honnen W., Singh S., Guerrini V., et al. Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells. medRxiv. 2021 doi: 10.1101/2021.04.11.21255153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.11.21255153</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval. BMJ. 2021;372:n326. doi: 10.1136/bmj.n326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n326</ArticleId><ArticleId IdType="pubmed">33536232</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., Baj A., Maggi F. Is a single COVID-19 vaccine dose enough in convalescents? Hum. Vaccines Immunother. 2021;17:2959&#x2013;2961. doi: 10.1080/21645515.2021.1917238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.1917238</ArticleId><ArticleId IdType="pmc">PMC8108188</ArticleId><ArticleId IdType="pubmed">33950788</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin A.T., Hanage W.P., Owusu-Boaitey N., Cochran K.B., Walsh S.P., Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and public policy implications. Eur. J. Epidemiol. 2020;35:1123&#x2013;1138. doi: 10.1007/s10654-020-00698-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-020-00698-1</ArticleId><ArticleId IdType="pmc">PMC7721859</ArticleId><ArticleId IdType="pubmed">33289900</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyanathan M., Afkhami S., Smaill F., Miller M.S., Lichty B.D., Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 2020;20:615&#x2013;632. doi: 10.1038/s41577-020-00434-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00434-6</ArticleId><ArticleId IdType="pmc">PMC7472682</ArticleId><ArticleId IdType="pubmed">32887954</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., Muller S., Kanduc D., David P., Halpert G., Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 2021;20:102792. doi: 10.1016/j.autrev.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariol A., Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus Infections. Immunity. 2020;53:248&#x2013;263. doi: 10.1016/j.immuni.2020.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.07.005</ArticleId><ArticleId IdType="pmc">PMC7359787</ArticleId><ArticleId IdType="pubmed">32717182</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown C.M., Vostok J., Johnson H., Burns M., Gharpure R., Sami S., Sabo R.T., Hall N., Foreman A., Schubert P.L., et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings&#x2014;Barnstable County, Massachusetts, July 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1059&#x2013;1062. doi: 10.15585/mmwr.mm7031e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7031e2</ArticleId><ArticleId IdType="pmc">PMC8367314</ArticleId><ArticleId IdType="pubmed">34351882</ArticleId></ArticleIdList></Reference><Reference><Citation>Group R.C., Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., et al. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2021;384:693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sholukh A.M., Fiore-Gartland A., Ford E.S., Miner M.D., Hou Y.J., Tse L.V., Kaiser H., Zhu H., Lu J., Madarampalli B., et al. Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays. J. Clin. Microbiol. 2021;59:JCM0052721. doi: 10.1128/JCM.00527-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00527-21</ArticleId><ArticleId IdType="pmc">PMC8451402</ArticleId><ArticleId IdType="pubmed">34288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandergaast R., Carey T., Reiter S., Lathrum C., Lech P., Gnanadurai C., Haselton M., Buehler J., Narjari R., Schnebeck L., et al. IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers. mSphere. 2021;6:e00170-21. doi: 10.1128/mSphere.00170-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00170-21</ArticleId><ArticleId IdType="pmc">PMC8265629</ArticleId><ArticleId IdType="pubmed">34077262</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett M., Yoder S., Brady E., Pulley J.M., Rhoads J.P., Stewart T.G., Bernard G.R., Creech C.B., Wheeler A.P., Thomsen I. A high-throughput liquid bead array assay confirms strong correlation between SARS-CoV-2 antibody level and COVID-19 severity. iScience. 2021;24:102052. doi: 10.1016/j.isci.2021.102052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.102052</ArticleId><ArticleId IdType="pmc">PMC7836362</ArticleId><ArticleId IdType="pubmed">33521603</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? Vaccine X. 2020;6:100076. doi: 10.1016/j.jvacx.2020.100076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2020.100076</ArticleId><ArticleId IdType="pmc">PMC7452821</ArticleId><ArticleId IdType="pubmed">32875286</ArticleId></ArticleIdList></Reference><Reference><Citation>Pia L. SARS-CoV-2-reactive T cells in patients and healthy donors. Nat. Rev. Immunol. 2020;20:353. doi: 10.1038/s41577-020-0333-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0333-2</ArticleId><ArticleId IdType="pmc">PMC7192054</ArticleId><ArticleId IdType="pubmed">32355329</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Mentzer A.J., Liu G., Yao X., Yin Z., Dong D., Dejnirattisai W., Rostron T., Supasa P., Liu C., et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 2020;21:1336&#x2013;1345. doi: 10.1038/s41590-020-0782-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0782-6</ArticleId><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>